Glimmer of hope for vaccine that could eradicate TB reinfection 20 December 2020 - 08:32 Image: Alaister Russell/The Sunday Times
Tuberculosis reinfection may be a thing of the past if a vaccine that is being developed by the University of Cape Town researchers proves successful.
The results from a clinical trial that is investigating a candidate vaccine that prevents the recurrence of TB in people who’ve recovered from the disease shows promise after it was proved safe and induced an immune response when given to cured patients.
The results of the phase 2 trial of the ID93+GLA-SE candidate vaccine, which have been published in the
New toolkit aims to maximize high-quality collection of thrombosis data in COVID-19 clinical studies
The ASH Research Collaborative (ASH RC) and the International Society of Haemostasis and Thrombosis (ISTH), two organizations with multidisciplinary expertise in blood clotting and bleeding disorders, have developed a toolkit to help clinical researchers from across medical disciplines design clinical trials that further the understanding of blood clotting events associated with COVID-19.
The new Toolkit for the Collection of Thrombosis-Related Data Elements in COVID-19 Clinical Studies, published today in Blood Advances, defines a series of endpoints - events or outcomes that are measured in a clinical study - that should be included in study design to collect and analyze important, relevant, and standardized data on dangerous blood clots that form in the veins or arteries of patients with COVID-19.
E-Mail
The ASH Research Collaborative (ASH RC) and the International Society of Haemostasis and Thrombosis (ISTH), two organizations with multidisciplinary expertise in blood clotting and bleeding disorders, have developed a toolkit to help clinical researchers from across medical disciplines design clinical trials that further the understanding of blood clotting events associated with COVID-19.
The new Toolkit for the Collection of Thrombosis-Related Data Elements in COVID-19 Clinical Studies, published today in Blood Advances, defines a series of endpoints - events or outcomes that are measured in a clinical study - that should be included in study design to collect and analyze important, relevant, and standardized data on dangerous blood clots that form in the veins or arteries of patients with COVID-19. The goal of this initiative is to maximize high-quality collection of COVID-19-associated clotting and bleeding events across diverse medical fields, such as internal medici